Q1 2025 CareDx Inc Earnings Call Transcript

Apr 30, 2025 / 08:30 PM GMT

Release Date Price: $16.88 (-6.89%)

Transcript 10-Q8-K

Key Points

Positve

CareDx Inc (CDNA) reported a strong first quarter with a revenue increase of 18% year over year, reaching $84.7 million.
The company achieved its seventh consecutive quarter of sequential testing volume growth, with testing services revenue up 15% year over year.
CareDx Inc (CDNA) ended the quarter with a robust cash balance of $231 million and no debt, providing financial stability.
The company launched two expanded indications for Allosure, enhancing its product offerings for pediatric heart transplant patients and simultaneous pancreas kidney transplant patients.
CareDx Inc (CDNA) made significant strides in market access, adding 3.5 million new covered lives for Allomap PAP and 15.5 million for Allosure testing.

Negative

Operating expenses increased, driven by investments in sales and marketing, which may impact profitability if not managed carefully.
The company faced a $1.1 million write-off for aged receivables, indicating potential challenges in collections.
CareDx Inc (CDNA) is involved in a securities class action litigation, with an anticipated out-of-pocket expense of approximately $5.4 million.
There was a muted start to the year in transplant procedures, which could impact future revenue growth if not addressed.
The company anticipates a $5 million annual investment for the Epic integration, which could strain resources if not offset by increased efficiencies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CDNA.OQ - CareDx Inc
Q1 2025 CareDx Inc Earnings Call
Apr 30, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Your program is about to begin. If you need assistance during your conference today, please press 0.

Good day everyone and welcome to today's CARDX 1st quarter 2025 earnings conference call.

At this time, all participants are in a listen-only mode. Later you have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing 1 on your telephone keypad.

You may withdraw yourself from the queue by pressing 2.

Please note this call may be recorded and I will be standing by if you should need any assistance.

It is now my pleasure to turn the conference over to Ms. Caroline Corner, Investor Relations. Please go ahead.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.